A review of phosphodiesterase type 5 inhibitors
Currently, three phosphodiesterase type 5 (PDE5) inhibitors are available for clinical use in South Africa; sildenafil, vardenafil and tadalafil. The PDE inhibitors are used in males to treat erectile dysfunction. However, sildenafil is also registered for use in the treatment of pulmonary hypertens...
Saved in:
Main Authors: | N. Schellack, A. Agoro |
---|---|
Format: | Article |
Language: | English |
Published: |
AOSIS
2014-05-01
|
Series: | South African Family Practice |
Subjects: | |
Online Access: | https://safpj.co.za/index.php/safpj/article/view/4050 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PHOSPHODIESTERASE-5 INHIBITORS USE IN PATIENTS WITH ERECTILE DYSFUNCTION AND CARDIOVASCULAR DISEASE IN CLINICAL PRACTICE
by: M. N. Mamedov, et al.
Published: (2016-01-01) -
Compound Xuanju capsules combined with phosphodiesterase-5 inhibitors as a new strategy for erectile dysfunction: a meta-analysis and trial sequential analysis
by: Ronghui Li, et al.
Published: (2025-06-01) -
Perioperative management with phosphodiesterase type 5 inhibitor and prostaglandin E1 for moderate portopulmonary hypertension following adult-to-adult living-donor liver transplantation: a case report
by: Takashi Onoe, et al.
Published: (2018-02-01) -
Prognosis and Treatment With Phosphodiesterase 5 Inhibitors in Combined Post‐ and Precapillary Pulmonary Hypertension: A Propensity Score‐Matched Analysis From the Hellenic Pulmonary Hypertension Registry
by: Georgios E. Papadopoulos, et al.
Published: (2025-04-01) -
PHARMACOTHERAPY IN PATIENTS WITH ERECTILE DYSFUNCTION AND BENIGN PROSTATIC HYPERPLASIA IN THE ABSENCE OF RISK OF DISEASE PROGRESSION
by: A. A. Kamalov, et al.
Published: (2018-03-01)